Janux Therapeutics Other Current Liabilities

The latest other current liabilities for JANX is $15M as of March 2026. That compares with $11M in the prior-year period — up 40.8% year over year. Investors often review this figure alongside Janux Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, JANX's other current liabilities moved from $11M to $15M — a 40.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Janux Therapeutics's operating scale or balance-sheet position.

A other current liabilities figure of $15M for JANX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting JANX's other current liabilities ($15M), review year-over-year change from $11M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Janux Therapeutics's other current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.